Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes.
JAK Inhibitors

(3R,4S)-Tofacitinib  
Cat. No.: HY-40354D

(3R,4S)-Tofacitinib is an enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.

Purity: >98%  
Clinical Data: No Development Reported  
Size: 5 mg

(3S,4S)-Tofacitinib  
Cat. No.: HY-40354B

(3S,4R)-Tofacitinib is an enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.

Purity: >98%  
Clinical Data: No Development Reported  
Size: 5 mg

AT9283  
Cat. No.: HY-50514

AT9283 is a multitargeted kinase inhibitor which potently inhibits aurora kinase A/B, JAK2/3 (IC₅₀=1.2 nM, 1.1 nM).

Purity: 99.61%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Atractylenolide I  
Cat. No.: HY-N0201

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties.

Purity: 99.08%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZ-3  
Cat. No.: HY-112442

AZ-3 is a potent and selective JAK1 inhibitor with an IC₅₀ of 34 nM.

Purity: >98%  
Clinical Data: No Development Reported  
Size: 250 mg, 500 mg

AZD-1480  
Cat. No.: HY-10193

AZD-1480 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC₅₀ of 1.3 and <0.4 nM, respectively.

Purity: 99.37%  
Clinical Data: Phase 1  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Baricitinib  
Cat. No.: HY-15315

Baricitinib is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

Purity: 99.93%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Baricitinib (INCB028050; LY3009104)

Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC₅₀ of 29 and 803 nM for JAK1 and JAK2, respectively.

Purity: 99.79%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg

Atractylodes macrocephala is a medicinal herb known for its traditional use in Chinese medicine. It possesses diverse bioactivities such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties.

Purity: >98%  
Clinical Data: No Development Reported  
Size: 250 mg, 500 mg

Abrocitinib is a selective and orally bioavailable JAK1 inhibitor. It inhibits JAK1 with an IC₅₀ of 0.45 nM.

Purity: 99.61%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC₅₀ of 29 and 803 nM for JAK1 and JAK2, respectively.

Purity: 99.79%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg

Abrocitinib (INCB028050; LY3009104) is a potent, orally active and selective JAK1 inhibitor, with IC₅₀ of 29 and 803 nM for JAK1 and JAK2, respectively.

Purity: 99.79%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg

AZ960  
Cat. No.: HY-10411

AZ960 is a potent and specific inhibitor of the JAK2 kinase with a Kᵢ of 0.45 nM.

Purity: 98.04%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 1 mg, 2 mg, 5 mg, 10 mg, 50 mg
<table>
<thead>
<tr>
<th><strong>Baricitinib phosphate</strong></th>
<th><strong>Cat. No.: HY-15315A</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Baricitinib phosphate is a selective orally bioavailable JAK1/JAK2 inhibitor with IC\textsubscript{50} of 5.9 nM and 5.7 nM, respectively.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.49%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BMS-066</strong></th>
<th><strong>Cat. No.: HY-18710</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC\textsubscript{50} of 9 nM and 72 nM, respectively.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>250 mg, 500 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BMS-911543</strong></th>
<th><strong>Cat. No.: HY-15270</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BMS-911543 is a selective JAK2 inhibitor, with IC\textsubscript{50} of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC\textsubscript{50} 75, 360, 66 nM, respectively).</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>98.12%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 2</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Brevilin A</strong></th>
<th><strong>Cat. No.: HY-N2095</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Brevilin A is a sesquiterpene lactone isolated from Centipeda minima with anti-tumor activity. Brevilin A is a selective inhibitor of JAK-STAT signal pathway by attenuating the JAKs activity and blocking STAT3 signaling (IC\textsubscript{50} = 10.6 μM) in Cancer Cells.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Cerdulatinib</strong></th>
<th><strong>Cat. No.: HY-15999</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerdulatinib (PRT062070; PRT2070) is a dual JAK and SYK inhibitor with IC\textsubscript{50} of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.00%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 2</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Curculigoside</strong></th>
<th><strong>Cat. No.: HY-N0705</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritis effects in vivo and in vitro via regulation of the JAK/STAT/NF-κB signaling pathway.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CEP-33779</strong></th>
<th><strong>Cat. No.: HY-15343</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC\textsubscript{50} of 1.8±0.6 nM.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>98.04%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CHZ868</strong></th>
<th><strong>Cat. No.: HY-18960</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CHZ868 is a type II JAK2 inhibitor with an IC\textsubscript{50} of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>98.33%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

www.MedChemExpress.com
**Decernotinib**  
*Cat. No.: HY-12469*

Decernotinib is a potent, orally active JAK3 inhibitor, with $K_i$ of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.

- **Purity:** 98.91%
- **Clinical Data:** Phase 3
- **Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

---

**Delgocitinib**  
*Cat. No.: HY-109053*

Delgocitinib is a novel and specific JAK inhibitor with $IC_{50}$s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

- **Purity:** 99.14%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Fedratinib**  
*Cat. No.: HY-10409*

Fedratinib (TG-101348; SAR 302503) is a selective inhibitor of JAK2 with an $IC_{50}$ of 3 nM, showing 35- and 334-fold selectivity over JAK1 and JAK3, respectively.

- **Purity:** 98.62%
- **Clinical Data:** Phase 2
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**FLLL32**  
*Cat. No.: HY-100544*

FLLL32, a synthetic analog of curcumin, is a JAK2/STAT3 dual inhibitor with anti-tumor activity.

- **Purity:** 99.78%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Filgotinib**  
*Cat. No.: HY-18300*

Filgotinib (GLPG0634) is a selective JAK1 inhibitor with $IC_{50}$ of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

- **Purity:** 99.64%
- **Clinical Data:** Phase 3
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Gandotinib**  
*Cat. No.: HY-13034*

Gandotinib (LY2784544) is a potent JAK2 inhibitor with $IC_{50}$ of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with $IC_{50}$ of 4, 25, 32, 44, and 95 nM.

- **Purity:** 99.96%
- **Clinical Data:** Phase 2
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**Ginsenoside Rk1**  
*Cat. No.: HY-N2515*

Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of JAK2/STAT3 signaling pathway and NF-κB.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

---

**GLPG0634 analog**  
*Cat. No.: HY-13961*

GLPG0634 (analog) (compound176) is a pan JAK inhibitor with $IC_{50}$s of 50-200 nM for JAK1/JAK2/JAK3; more information can be found in the reference patents.

- **Purity:** 98.00%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

---

**Gusacitinib**  
*Cat. No.: HY-103018*

Gusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinase (JAK) with $IC_{50}$ values of 5-46 nM.

- **Purity:** 99.41%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg
Ilgininib (NS-018)  
Cat. No.: HY-19631A

Ilgininib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC_{50} of 0.72 nM, 46-54%, and 31-fold selectivity for JAK2 over JAK1 (IC_{50} 33 nM), JAK3 (IC_{50} 39 nM), and Tyk2 (IC_{50} 22 nM).

Purity: 95.88%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ilgininib maleate  
(NS-018 maleate)  
Cat. No.: HY-19631

Ilgininib (maleate) (NS-018 (maleate)) is a highly active and orally bioavailable JAK2 inhibitor, with an IC_{50} of 0.72 nM, 46-54%, and 31-fold selectivity for JAK2 over JAK1 (IC_{50} 33 nM), JAK3 (IC_{50} 39 nM), and Tyk2 (IC_{50} 22 nM).

Purity: 97.04%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Itacitinib adipate  
Cat. No.: HY-16997A

Itacitinib adipate is an orally bioavailable and selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.

Purity: 99.37%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JAK-IN-1  
Cat. No.: HY-U00277

JAK-IN-1 is a JAK1/2/3 inhibitor with IC_{50} of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.

Purity: >98%  
Clinical Data: No Development Reported  
Size: 250 mg, 500 mg

JAK-IN-4  
Cat. No.: HY-111749

JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.

Purity: >98%  
Clinical Data: No Development Reported  
Size: 100 mg, 250 mg, 500 mg

www.MedChemExpress.com
### JAK-IN-5
Cat. No.: HY-111471

JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.

| Purity:      | >98%        |
| Clinical Data: | No Development Reported |
| Size:        | 250 mg, 500 mg |

### JAK-IN-3
Cat. No.: HY-107361

JAK1-IN-3 is a selective JAK1 inhibitor, with an IC\(_{50}\) of 73 nM, weakly inhibits JAK2, and shows little inhibition on JAK3 (IC\(_{50}\) >14.7, >30 μM, respectively).

| Purity:      | 99.32%      |
| Clinical Data: | No Development Reported |
| Size:        | 5 mg, 10 mg, 50 mg, 100 mg |

### JAK1-IN-7
Cat. No.: HY-126294

JAK1-IN-7 is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.

| Purity:      | >98%        |
| Clinical Data: | No Development Reported |
| Size:        | 100 mg, 250 mg, 500 mg |

### JAK3 covalent inhibitor-1
Cat. No.: HY-119935

JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC\(_{50}\) of 11 nM and shows 246-fold selectivity vs other JAKs.

| Purity:      | >98%        |
| Clinical Data: | No Development Reported |
| Size:        | 100 mg, 250 mg, 500 mg |

### JAK-In-6
Cat. No.: HY-101976

JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC\(_{50}\) of 0.15 nM.

| Purity:      | >98%        |
| Clinical Data: | No Development Reported |
| Size:        | 250 mg, 500 mg |

### JAK/HDAC-IN-1
Cat. No.: HY-126141

JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC\(_{50}\)s of 4 and 2 nM for JAK2 and HDAC, respectively.

| Purity:      | 98.04%      |
| Clinical Data: | No Development Reported |
| Size:        | 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

### JAK1-IN-4
Cat. No.: HY-116505

JAK1-IN-4 is a potent and selective JAK1 inhibitor, with IC\(_{50}\)s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC\(_{50}\), 227 nM).

| Purity:      | >98%        |
| Clinical Data: | No Development Reported |
| Size:        | 250 mg, 500 mg |

### JAK2-IN-4
Cat. No.: HY-100759

JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC\(_{50}\) values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.

| Purity:      | >98%        |
| Clinical Data: | No Development Reported |
| Size:        | 100 mg, 250 mg, 500 mg |

### JAK3-IN-1
Cat. No.: HY-19544

JAK3-IN-1 is a potent JAK3 inhibitor with IC\(_{50}\) of 4.8 nM, also inhibits JAK1 (IC\(_{50}\) = 896 nM) and JAK2 (IC\(_{50}\) = 1050 nM). IC\(_{50}\) value: 4.8 nM Target: JAK3-IN-1 provides a set of useful tools to pharmacologically interrogate JAK3-dependent biology.

| Purity:      | 99.98%      |
| Clinical Data: | No Development Reported |
| Size:        | 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

### JAK3-IN-7
Cat. No.: HY-126181

JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, compound example 283.

| Purity:      | >98%        |
| Clinical Data: | No Development Reported |
| Size:        | 1 mg, 5 mg, 10 mg |

---

**Fax:** 609-228-5909  
**Tel:** 609-228-6898  
**Email:** sales@MedChemExpress.com
**JANEX-1**  
(HE-P131; Jak3 inhibitor I)  
Cat. No.: HY-15508

JANEX-1 is a potent and specific JAK3 inhibitor (estimated $K_i$=2.3 μM). JANEX-1 (HE-P131) shows potent JAK3-inhibitory activity ($IC_{50}$ of 78 μM), does not inhibit JAK1 and JAK2.

**Purity:** 99.84%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

---

**LFM-A13**  
Cat. No.: HY-18009

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plk1 and PLK3 with $IC_{50}$ of 2.5 μM, 10 μM and 61 μM, LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

**Purity:** 99.70%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

---

**Momelotinib Mesylate**  
(CYT387 Mesylate)  
Cat. No.: HY-10963

Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with $IC_{50}$ of 11 nM and 18 nM, respectively. CYT387 shows much less activity against JAK3.

**Purity:** >98%  
**Clinical Data:** Phase 3  
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

**NSC 42834**  
(JAK2 Inhibitor V; Z3)  
Cat. No.: HY-15480

NSC 42834 is a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

**Purity:** 95.5%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg

---

**NVP-BSK805 dihydrochloride**  
(BSK805 dihydrochloride)  
Cat. No.: HY-14722A

NVP-BSK805 dihydrochloride is an ATP-competitive JAK2 inhibitor, with $IC_{50}$ of 0.48 nM, 31.63 nM, 18.68 nM and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

**Purity:** 99.36%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**Oclacitinib maleate**  
(PF-03394197 maleate)  
Cat. No.: HY-13577

Oclacitinib maleate is a novel JAK inhibitor. Oclacitinib is most potent at inhibiting JAK1 ($IC_{50}=10$ nM).

**Purity:** 99.53%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**Lestaurtinib**  
(CEP-701; KT-5555)  
Cat. No.: HY-50867

Lestaurtinib (CEP-701;KT-5555) is a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits JAK2, FLT3 and TrkA with $IC_{50}$ of 0.9, 3 and less than 25 nM, respectively.

**Purity:** >99.0%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 1 mg, 5 mg

---

**Momelotinib**  
(CYT387)  
Cat. No.: HY-10961

Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with $IC_{50}$ of 11 nM and 18 nM, respectively. CYT387 shows much less activity against JAK3.

**Purity:** 98.11%  
**Clinical Data:** Phase 3  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

---

**Momelotinib sulfate**  
(CYT387 (sulfate salt))  
Cat. No.: HY-10962

Momelotinib sulfate (CYT387 sulfate) is an ATP-competitive inhibitor of JAK1/JAK2 with $IC_{50}$ of 11 nM and 18 nM, 10-fold selectivity versus JAK3 ($IC_{50}=155$ nM).

**Purity:** >96.0%  
**Clinical Data:** Phase 3  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
Pacritinib (SB1518)
Cat. No.: HY-16379
Pacritinib is a potent inhibitor of both wild-type JAK2 (IC_{50}=23 nM) and JAK2^{D835Y} mutant (IC_{50}=19 nM). Pacritinib also inhibits FLT3 (IC_{50}=22 nM) and its mutant FLT3^{ITR} (IC_{50}=6 nM).

Purity: 99.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-06263276
Cat. No.: HY-101024
PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC_{50}s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PF-06700841
Cat. No.: HY-112708
PF-06700841 is a dual JAK1 and TYK2 inhibitor with IC_{50}s of 17 and 23 nM, respectively. Anti-inflammatory activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Protosappanin A (PTA)
Cat. No.: HY-113573
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.

Purity: 98.88%
Clinical Data: No Development Reported
Size: 5 mg

RGB-286638
Cat. No.: HY-15504
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.

Purity: 98.60%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Peficitinib (ASPC05K; JNU-54781532)
Cat. No.: HY-19568
Peficitinib is an oral JAK inhibitor, with IC_{50}s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

Purity: 99.43%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-06651600
Cat. No.: HY-100754
PF-06651600 is a potent JAK3-selective inhibitor with an IC_{50} of 33.1 nM.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PF-06700841 P-Tosylate
Cat. No.: HY-112708A
PF-06700841 P-Tosylate is a dual JAK1 and TYK2 inhibitor with IC_{50}s of 17 and 23 nM, respectively. Anti-inflammatory activity.

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pyridone 6 (CMP 6; JAK Inhibitor)
Cat. No.: HY-14435
Pyridone 6 is a pan-JAK inhibitor, which potently inhibits the JAK kinase family, with IC_{50}s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

RGB-286638 free base
Cat. No.: HY-15504A
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.

Purity: 98.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
Ruxolitinib
(INCB018424)
Cat. No.: HY-50856
Ruxolitinib is a potent and selective JAK1/2 inhibitor with IC_{50} of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3.
Purity: 99.99%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib S enantiomer
(S-Ruxolitinib; INCB18424)
Cat. No.: HY-50856A
Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC_{50} of 3.3 nM/2.8 nM in cell-free assays.
Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 1 mg, 5 mg

SAR-20347
Cat. No.: HY-100895
SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC_{50} of 0.6, 23, 26 and 41 nM, respectively.
Purity: 97.00%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Solcitinib
(GSK-2586184; GLPG-0778)
Cat. No.: HY-16755
Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC_{50} of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tofacitinib
tasocitinib; CP-690550)
Cat. No.: HY-40354
Tofacitinib is an orally available JAK3/2/1 inhibitor with IC_{50} of 1, 20, and 112 nM, respectively.
Purity: 99.96%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Ruxolitinib phosphate
(INCB018424 phosphate)
Cat. No.: HY-50858
Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC_{50} of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.
Purity: 99.89%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib sulfate
(INCB018424 sulfate)
Cat. No.: HY-50859
Ruxolitinib sulfate is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC_{50} of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.
Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

SB1317
(TG02)
Cat. No.: HY-15166
SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 for the treatment of cancer, with IC_{50} of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.
Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TG101209
Cat. No.: HY-10410
TG101209 is a selective JAK2 inhibitor with IC_{50} of 6 nM, less potent to FLT3 and RET with IC_{50} of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.
Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tofacitinib citrate
(Tasocitinib citrate; CP-690550 citrate)
Cat. No.: HY-40354A
Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC_{50} of 1, 20, and 112 nM, respectively.
Purity: 99.92%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg
TyK2-IN-2
Cat. No.: HY-101762
Tyk2-IN-2 is an inhibitor of TYK2, used for treatment of inflammatory and autoimmune diseases.

Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tyk2-IN-3
Cat. No.: HY-18709
Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC50 of 485 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Tyk2-IN-5
Cat. No.: HY-111745
Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Kd of 0.086 nM for Tyk2, JH2 and an IC50 of 25 nM for IFNα.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyk2-IN-7
Cat. No.: HY-126242S
Tyk2-IN-7 (Compound 48) is a Tyk2 JH2 Inhibitor, binds to Tyk2 JH2 domain with IC50 and Kd of 0.00053 μM and 0.00007 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Tyk2-IN-8
Cat. No.: HY-126290
Tyk2-IN-8 (compound 10) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain with an IC50 of 17 nM, used in the treatment of psoriasis.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Upadacitinib (ABT-494)
Cat. No.: HY-19569
Upadacitinib (ABT-494) is a potent and selective Janus kinase 1 (JAK1) inhibitor, with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders.

Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WHI-P154
Cat. No.: HY-13895
WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC50 of 4 nM and 1.8 μM, respectively.

Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WHI-P97
Cat. No.: HY-11067
WHI-P97 is a rationally designed potent inhibitor of JAK-3.

Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

WP1066
Cat. No.: HY-15312
WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.

Purity: 99.67%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

XLO19
Cat. No.: HY-13777
XLO19 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1, shows good biochemical and cellular potency against JAK2 with good selectivity against the Janus Kinase family as well as a broad kinase panel.

Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
ZM39923

Cat. No.: HY-12589A

ZM39923 is a JAK3 inhibitor, with a \( pIC_{50} \) of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an \( IC_{50} \) of 10 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

ZM39923 hydrochloride

Cat. No.: HY-12589

ZM39923 hydrochloride is a JAK3 inhibitor, with a \( pIC_{50} \) of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (TGM2) with an \( IC_{50} \) of 10 nM.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg